parathyroid hormone

An arrow incrementally going up stairs before pointing straight up Blue background
Biotech

AstraZeneca's $800M rare disease bet hits primary phase 3 goal

The update keeps eneboparatide on track, but the lack of data leaves questions about its positioning versus Ascendis Pharma’s Yorvipath unanswered.
Nick Paul Taylor Mar 17, 2025 7:25am
gray metal bridge

BridgeBio plots next steps for hypoparathyroidism drug

Mar 22, 2021 7:35am
boardroom

Former Merck clinical VP joins Entera Bio as CMO

Sep 24, 2018 8:50am